KalVista Prescription drugs, Inc. (NASDAQ:KALV) Q1 2026 Earnings Name September 11, 2025 8:30 AM EDT
Firm Individuals
Ryan Baker – Head of Investor Relations
Benjamin Palleiko – CEO & Director
Nicole Sweeny – Chief Business Officer
Brian Piekos – Chief Monetary Officer
Paul Audhya – Chief Medical Officer
Convention Name Individuals
Stacy Ku – TD Cowen, Analysis Division
Paul Matteis – Stifel, Nicolaus & Firm, Included, Analysis Division
Tazeen Ahmad – BofA Securities, Analysis Division
Maurice Raycroft – Jefferies LLC, Analysis Division
Will Soghikian – Leerink Companions LLC, Analysis Division
Pete Stavropoulos – Cantor Fitzgerald & Co., Analysis Division
Serge Belanger – Needham & Firm, LLC, Analysis Division
Debanjana Chatterjee – JonesTrading Institutional Providers, LLC, Analysis Division
Catherine Okoukoni – Residents JMP Securities, LLC, Analysis Division
Presentation
Operator
Women and gents, thanks for standing by. Welcome to KalVista Prescription drugs operational replace and First Fiscal Quarter Monetary Outcomes. [Operator Instructions] Please be suggested that right this moment’s convention is being recorded.
I might now like to show the convention over to Ryan Baker, Head of Investor Relations. Sir, please go forward.
Ryan Baker
Head of Investor Relations
Thanks, operator. Good morning, everybody, and thanks for becoming a member of us to debate KalVista Prescription drugs fiscal 12 months 2026 first quarter monetary replace and working outcomes. Please observe we’ll be guaranteeing forward-looking statements right this moment. We refer you to KalVista’s SEC filings for a dialogue of the dangers that will trigger precise outcomes to vary from the forward-looking statements.
On the decision with me right this moment from KalVista are Ben Palleiko, Chief Government Officer; Nicole Sweeny, Chief Business Officer; and Brian Piekos, Chief Monetary Officer. Dr. Paul Audhya, our Chief Medical Officer, might be becoming a member of us for the Q&A portion of the decision.
Ben will start with a assessment of the corporate’s progress throughout the 3 months ended July 31, 2025, together with FDA approval of EKTERLY and different regulatory
